Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 2/20 | 0.59 |
| ▸ | APLNR | P35414 | 2/20 | 0.51 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.50 |
| ▸ | GLP1R | P43220 | 3/20 | 0.49 |
| ▸ | GCGR | P47871 | 3/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.47 |
| ▸ | CALCR | P30988 | 3/20 | 0.47 |
| ▸ | RAMP1 | O60894 | 1/20 | 0.47 |
| ▸ | RAMP2 | O60895 | 1/20 | 0.47 |
| ▸ | RAMP3 | O60896 | 1/20 | 0.47 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.47 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30439872 | 0.92 | C5AR1 (0.60) | C5AR1GLP1RGCGROPRD1CALCR | |
| SCHEMBL30440019 | 0.90 | C5AR1 (0.66) | C5AR1GLP1RGCGRIL23RCXCR4 | |
| SCHEMBL30439960 | 0.89 | C5AR1 (0.57) | C5AR1GLP1RGCGROPRD1CALCR | |
| SCHEMBL30439789 | 0.89 | C5AR1 (0.65) | C5AR1GLP1RGCGRIL23RCXCR4 | |
| SCHEMBL30440071 | 0.89 | C5AR1 (0.63) | C5AR1GLP1RGCGRIL23RCXCR4 | |
| SCHEMBL30440028 | 0.87 | C5AR1 (0.64) | C5AR1GLP1RGCGRIL23RCXCR4 | |
| SCHEMBL30439962 | 0.87 | C5AR1 (0.61) | C5AR1PIN1GLP1RGCGRCXCR4 | |
| SCHEMBL30439942 | 0.87 | C5AR1 (0.61) | C5AR1GLP1RGCGRCXCR4 | |
| SCHEMBL30440014 | 0.86 | IL23R (0.59) | C5AR1PIN1GLP1RIL23RCXCR4 | |
| SCHEMBL30439961 | 0.85 | C5AR1 (0.55) | C5AR1APLNRPIN1GLP1RGCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230173086-A1 | PEPTIDE CONJUGATES AND THERAPEUTIC AGENTS HAVING IMPROVED PHARMACOLOGICAL AND PHARMACOKINETIC PROPERTIES | EAGLE RESOLUTE INVESTMENT LLC | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230173086-A1 | PEPTIDE CONJUGATES AND THERAPEUTIC AGENTS HAVING IMPROVED PHARMACOLOGICAL AND PHARMACOKINETIC PROPERTIES | VIP, DNPEP, CD74 | C5AR1 140/4885APLNR 189/4885PIN1 1211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.